A recently published article in Wounds
The peer-reviewed article "The in vitro antibiofilm performance of ChloraSolv® Wound Debridement Gel" (authors Dr
The article concludes that ChloraSolv showed notably greater antibiofilm activity compared to other debridement techniques/products. Although this study only examined the in vitro antibiofilm activity of ChloraSolv, in conjunction with recent clinical studies which focused on easier debridement of devitalised tissue, it highlights the promise for this new wound debridement gel which combines tissue softening and antibiofilm activity.
"We are pleased to see the conclusions from the article, specifically on the superior antibiofilm activity of ChloraSolv compared with other wound debridement techniques/products available to healthcare professionals. The results further strengthens the evidence that ChloraSolv enables convenient, effective and gentle debridement by combining the softening of devitalised tissue with antibiofilm activity", says
TRADING PLACE AND CERTIFIED ADVISER:
FOR MORE INFORMATION, PLEASE CONTACT:
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25
ABOUT
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at rls.global
https://news.cision.com/rls-global-ab/r/chlorasolv-shows-notably-greater-antibiofilm-activity-in-vitro-compared-to-other-debridement-product,c3736796
https://mb.cision.com/Main/12052/3736796/1925461.pdf
https://mb.cision.com/Public/12052/3736796/964552ba32d08d59.pdf
(c) 2023 Cision. All rights reserved., source